Ceramide Analogs as Apoptotic Agents for the Treatment of Prostate Cancer

Dagan Arie, HUJI, School of Medicine - IMRIC

Validated approach in small animals and human cell models



Ceramide, apoptosis, cancer, sphingolipids, prostate cancer

Development Stage

Considerable anticancer activity in vivo in prostate, colon, pancreas and melanoma mouse models of human tumors. In vitro activity in various human cancer cell lines.



  • Novel new compounds
  • Considerable anticancer activity observed with local or even in metastatic cancer of prostate, colon, pancreas and melanoma mice models. Analog were injected intradermally or intraperitoneally or given per os to mice bearing human tumors.
  • Provides powerful stand alone or adjunctive therapy with irradiation or chemotherapy for cancer
  • Elevates cellular ceramide, inducing cytotoxicity and death by apoptosis
  • Leverages proven treatment models


Our Innovation

  • Synthetic compounds activate procaspase-3 and induce apoptosis
  • Increases the caspase-3 activity six to seven fold
  • Treatment with an analogue resulted in tumor regression in mice


The Opportunity

  • Higher efficiency for cancer treatment
  • Attenuates treatment process, reducing patient discomfort
  • Addresses needs for further expand to cancer market


Development Milestones

  • Further in vivo mouse models
  • Pharmacokinetic pharmacodynamic experiments
  • Progress to In vivo human testing


Patent Status

Granted US 8,962,891; US 9,340,488; Europe 2217560

Contact for more information:

Ariela Markel
VP, Business Development, Healthcare
Contact ME: